Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Dermatologic 1

Conditions

Breast Neoplasms 5Melanoma 2Squamous Cell Carcinoma of Head and Neck 1Prostatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Moderate Hepatic Impairment 1Metastatic Castration-resistant Prostate Cancer (mCRPC) 1Meningioma 1Lymphoma 1Locally Advanced (Inoperable) or Metastatic Breast Cancer 1Leukemia 1Healthy Participants 1Endometrial Neoplasms 1Disease Progression 1Chondrosarcoma 1CCCA Assessed by Ki67 Drop Below <2.7% From Baseline 1

Interventions

regorafenib 1enasidenib 1capivasertib 1abemaciclib 1Weight-Bearing 1Taxes 1Standard of Care 1Range of Motion, Articular 1Paclitaxel 1Immunoglobulin G 1Immune Checkpoint Inhibitors 1Disulfides 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Chondrosarcoma × capivasertib × Clear all
NCT05039801 2026-04-15

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center

Phase 1 Recruiting
54 enrolled
DermatologicGynecologicHead & NeckSarcoma

Squamous Cell Carcinoma of Head and Neck, Chondrosarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡